Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results. Schlosser AR, Shareef M, Olydam J, Nijsten TEC, et al. Clin Exp Dermatol 2023 Jan 26:llad038. doi: 10.1093.

Read + Share

Amedeo Smart

Independent Medical Education

Schlosser AR, Shareef M, Olydam J, Nijsten TEC, et al. Tralokinumab for moderate-to-severe atopic dermatitis patients: first daily practice results. Clin Exp Dermatol 2023 Jan 26:llad038. doi: 10.1093.
PMID: 36702810